Open AccessPeriostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer
Author(s) -
Dong Dong,
Jia Li,
Zhang Lufang,
Ma Na,
Zhang Aimin,
Zhou Yunli,
Ren Li
Publication year - 2018
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13712
Subject(s) - periostin , ca19 9 , pancreatic cancer , medicine , biomarker , carcinoembryonic antigen , receiver operating characteristic , area under the curve , gastroenterology , oncology , pathology , cancer , biology , extracellular matrix , biochemistry , microbiology and biotechnology
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with few biomarkers to guide treatment options. Carbohydrate antigen 19.9 (CA19.9), the most frequently used biomarker for PDAC, is not sensitive and specific enough for the detection of the disease. This study aimed to evaluate serum periostin (POSTN) and CA242 as potential diagnostic biomarkers complementing CA19.9 in detecting pancreatic cancer. Blood samples were from 362 participants, including 213 patients with different stages of PDAC, 75 patients with benign pancreatic disease, and 74 healthy individuals. All samples were randomly divided into a training set and a validation set. Carbohydrate antigen 19.9, CA242, POSTN, as well as carcinoembryonic antigen, were measured by ELISA or automated immunoassay. The receiver operating characteristic curve analysis revealed that the performance of CA19.9 in the validation group were improved by the marker panel composed of CA19.9, POSTN, and CA242, to discriminate early stage PDAC not only from healthy controls (area under the curve [AUC] CA19.9 = 0.94 vs AUC CA19.9 + POSTN + CA242 = 0.98, P < .05) but also from benign conditions (AUC CA19.9 = 0.87 vs AUC CA19.9 + POSTN + CA242 = 0.90, P < .05). In addition, POSTN retained significant diagnostic capabilities to distinguish PDAC CA19.9‐negative from healthy controls (AUC POSTN = 0.87) as well as from benign conditions (AUC POSTN = 0.84) in the whole set. This study suggested that POSTN and CA242 are potential diagnostic serum biomarkers complementing CA19.9 in detecting early pancreatic cancer.